

Xiaoyan Si

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8576029/publications.pdf>

Version: 2024-02-01

44
papers

507
citations

759233

12
h-index

752698

20
g-index

58
all docs

58
docs citations

58
times ranked

693
citing authors

#	ARTICLE	IF	CITATIONS
1	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. <i>Thoracic Cancer</i> , 2022, 13, 1059-1066.	1.9	2
2	Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period. <i>Thoracic Cancer</i> , 2022, 13, 539-548.	1.9	5
3	Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with) Tj ETQq1 1 0.784314 rgBT /Overlock 1 small cell lung cancer: A phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8573-8573.	1.6	0
4	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. <i>Cancer Medicine</i> , 2021, 10, 188-198.	2.8	11
5	Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 357-363.	1.9	15
6	Non-small cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report. <i>Thoracic Cancer</i> , 2021, 12, 1244-1247.	1.9	4
7	Immune checkpoint inhibitor-related epidermal necrolysis: A rare condition with poor prognosis. <i>European Journal of Cancer</i> , 2021, 145, 194-196.	2.8	8
8	Myocarditis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14579-e14579.	1.6	0
9	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 488-492.	1.9	17
10	Management of immune checkpoint inhibitor-related rheumatic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 198-202.	1.9	2
11	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020, 11, 191-197.	1.9	52
12	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. <i>Thoracic Cancer</i> , 2020, 11, 475-480.	1.9	9
13	Use of glucocorticoids in the management of immunotherapy-related adverse effects. <i>Thoracic Cancer</i> , 2020, 11, 3047-3052.	1.9	13
14	<p></p>NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5975-5985.	1.9	7
15	Pulmonary and Skeletal Infection of <i>Mycobacterium kansasii</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1169-1170.	5.6	1
16	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , 2020, 11, 2077-2086.	1.9	1
17	A phase III, randomized, double-blind, controlled trial of carboxamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	3.2	7
18	Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2020, 11, 1869-1875.	1.9	1

#	ARTICLE	IF	CITATIONS
19	Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum+emetrexed: The first report of two cases. Thoracic Cancer, 2020, 11, 2339-2342.	1.9	3
20	Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. Thoracic Cancer, 2020, 11, 1216-1223.	1.9	5
21	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. Thoracic Cancer, 2020, 11, 829-834.	1.9	5
22	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. Thoracic Cancer, 2020, 11, 799-804.	1.9	24
23	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thoracic Cancer, 2020, 11, 810-818.	1.9	19
24	Clinical diagnosis and treatment of immune checkpoint inhibitor-related endocrine dysfunction. Thoracic Cancer, 2020, 11, 1099-1104.	1.9	5
25	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thoracic Cancer, 2020, 11, 805-809.	1.9	8
26	Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. Thoracic Cancer, 2020, 11, 594-602.	1.9	14
27	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. Thoracic Cancer, 2020, 11, 498-504.	1.9	10
28	Histologic transformation of lung cancer during pembrolizumab therapy: A case report. Thoracic Cancer, 2020, 11, 793-796.	1.9	10
29	Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. Thoracic Cancer, 2020, 11, 1746-1751.	1.9	11
30	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. Thoracic Cancer, 2020, 11, 1647-1654.	1.9	18
31	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. Thoracic Cancer, 2020, 11, 1621-1632.	1.9	44
32	Opportunistic infections complicating immunotherapy for non-small cell lung cancer. Thoracic Cancer, 2020, 11, 1689-1694.	1.9	11
33	EGFR T790M detection in formalin-fixed paraffin-embedded tissues of patients with lung cancer using RNA-based in situ hybridization: A preliminary feasibility study. Thoracic Cancer, 2019, 10, 1936-1944.	1.9	7
34	Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease. OncoTargets and Therapy, 2019, Volume 12, 5545-5549.	2.0	4
35	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thoracic Cancer, 2019, 10, 551-556.	1.9	42
36	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. OncoTargets and Therapy, 2018, Volume 11, 7513-7519.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. <i>Lung Cancer</i> , 2018, 125, 142-149.	2.0	34
38	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 32-37.	2.0	32
39	Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. <i>Lung Cancer</i> , 2018, 122, 1-6.	2.0	17
40	Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018, 9, 1056-1061.	1.9	7
41	Rebiopsy status among non-small cell lung cancer patients after Icotinib therapy in China.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21146-e21146.	1.6	0
42	The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20613-e20613.	1.6	7
43	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19070-e19070.	1.6	0
44	Safety and efficacy of cetuximab combined with chemotherapy in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2012, 3, 188-193.	1.9	0